Key terms

About TWST

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest TWST news

Apr 12 8:12pm ET Cathie Wood’s ARK Investment bought 133K shares of Twist Bioscience today Mar 28 8:18pm ET Cathie Wood’s ARK Investment bought 114K shares of Twist Bioscience today Mar 25 8:17pm ET Cathie Wood’s ARK Investment bought 129K shares of Twist Bioscience today Mar 21 2:37am ET Buy Rating Justified: Twist Bioscience’s Strong Demand and Strategic Expansion Signal Market Share Growth Mar 05 1:23am ET Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT) Feb 08 4:41am ET Twist Bioscience Shareholders Elect Directors, Approve Compensation Feb 07 10:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Walgreens Boots Alliance (WBA) and Twist Bioscience (TWST) Feb 06 8:19am ET Twist Bioscience and Element Biosciences team on Exome sequencing solutions Feb 06 8:16am ET Twist debuts cfDNA library preparation kit for liquid biopsy applications Feb 06 3:35am ET Buy Rating for Twist Bioscience on Strong Financial Performance and Positive Business Outlook Feb 05 7:50am ET Analysts’ Top Healthcare Picks: Premier (PINC), Twist Bioscience (TWST) Feb 05 7:31am ET Twist Bioscience price target raised to $43 from $30 at Scotiabank Feb 05 6:49am ET Twist Bioscience price target raised to $38 from $27 at Baird Feb 05 2:56am ET Twist Bioscience (TWST) Gets a Buy from Barclays Feb 03 1:09pm ET Twist Bioscience price target raised to $25 from $19 at JPMorgan Feb 03 12:48pm ET Maintaining Sell Rating on Twist Bioscience Amid Revenue Outperformance and Uncertain Margin Targets Feb 02 11:35am ET Twist Bioscience: A Strong Buy on Surpassing Financials and Growth Potential Feb 02 7:43am ET Twist Bioscience sees Q2 revenue $70M-$71M, consensus $70.09M Feb 02 7:41am ET Twist Bioscience raises FY24 revenue view to $288M-$293M from $285M-$290M Feb 02 7:36am ET Twist Bioscience reports Q1 EPS (75c), consensus (78c) Feb 02 7:05am ET Options Volatility and Implied Earnings Moves Today, February 02, 2024 Jan 24 8:17am ET Twist Bioscience expands express genes rapid synthesis service Jan 24 7:20am ET Twist Bioscience price target raised to $45 from $30 at Barclays Jan 17 4:48am ET Twist Bioscience upgraded to Buy from Neutral at Goldman Sachs

No recent press releases are available for TWST

TWST Financials

1-year income & revenue

Key terms

TWST Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TWST Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms